Pages that link to "Q43689965"
Jump to navigation
Jump to search
The following pages link to Effects of long-term alendronate treatment on postmenopausal osteoporosis bone material properties (Q43689965):
Displayed 8 items.
- Long-term safety of antiresorptive treatment: bone material, matrix and mineralization aspects (Q27025945) (← links)
- Randomized clinical trial comparing efficacy and safety of brand versus generic alendronate (Bonmax®) for osteoporosis treatment (Q33874055) (← links)
- Presence of pyrophosphate in bone from an atypical femoral fracture site: A case report. (Q37720674) (← links)
- Bone's Material Constituents and their Contribution to Bone Strength in Health, Disease, and Treatment. (Q38364893) (← links)
- Baseline mineralizing surface determines the magnitude of the bisphosphonate effect on cortical bone mineralization in postmenopausal osteoporotic patients (Q38599112) (← links)
- Insights into the bisphosphonate holiday: a preliminary FTIRI study (Q46987405) (← links)
- Alendronate promotes osteoblast differentiation and bone formation in ovariectomy-induced osteoporosis through interferon-β/signal transducer and activator of transcription 1 pathway (Q49460312) (← links)
- Zebrafish as an Emerging Model for Osteoporosis: A Primary Testing Platform for Screening New Osteo-Active Compounds (Q61806983) (← links)